Puma Biotechnology Aktie

Kaufen

Verkaufen

3,75 EUR -0,06 EUR -1,47 %

12:12:21

BER

4,43 USD -0,09 USD -1,99 %

19.09.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.189,59 Mio. EUR

KGV4,95Div. Rendite0,00%

WKNA1J643

ISINUS74587V1070

SymbolPBYI

Puma Biotechnology Aktien News

Sortieren:Datum Meistgelesen

03.01.25BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

23.12.24BusinesswirePuma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

04.12.24BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

20.11.24BusinesswirePuma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

07.11.24BusinesswirePuma Biotechnology Reports Third Quarter 2024 Financial Results

05.11.24BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

24.10.24BusinesswirePuma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

03.09.24BusinesswirePuma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

06.08.24BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

01.08.24BusinesswirePuma Biotechnology Reports Second Quarter Financial Results

18.07.24BusinesswirePuma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

02.07.24BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

07.06.24BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

03.06.24BusinesswirePuma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

02.06.24BusinesswirePuma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

28.05.24BusinesswirePuma Biotechnology to Join Russell 3000 Index

23.05.24BusinesswirePuma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

02.05.24BusinesswirePuma Biotechnology Reports First Quarter Financial Results

18.04.24BusinesswirePuma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

03.04.24BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

20.03.24BusinesswirePuma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

29.02.24BusinesswirePuma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

28.02.24BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

15.02.24BusinesswirePuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

13.02.24BusinesswirePuma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

11.01.24BusinesswirePuma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

11.12.23BusinesswirePuma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

06.11.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02.11.23BusinesswirePuma Biotechnology Reports Third Quarter 2023 Financial Results

19.10.23BusinesswirePuma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

04.10.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

21.09.23BusinesswirePuma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

31.08.23BusinesswirePuma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

08.08.23BusinesswirePuma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

03.08.23BusinesswirePuma Biotechnology Reports Second Quarter Financial Results

20.07.23BusinesswirePuma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

06.06.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

05.05.23BusinesswirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04.05.23BusinesswirePuma Biotechnology Reports First Quarter Financial Results

20.04.23BusinesswirePuma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

Puma Biotechnology News

Puma Biotechnology News: auf dieser Seite finden Sie alle Puma Biotechnology News und Nachrichten zur Puma Biotechnology Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Puma Biotechnology News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Puma Biotechnology News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.